3/27/2023 0 Comments Simpletor corp201000011510 cancer Diseases 0.000 title claims abstract description 136.239000003757 phosphotransferase inhibitor Substances 0.000 title claims abstract description 209.229920003245 polyoctenamer Polymers 0.000 title claims abstract description 214.102100017734 RORC Human genes 0.000 title claims abstract description 214.Assignors: HEGE, KRISTEN MAE, RAYMON, HEATHER, CHOPRA, RAJESH Publication of US20140314753A1 publication Critical patent/US20140314753A1/en Application granted granted Critical Publication of US9474757B2 publication Critical patent/US9474757B2/en Status Active legal-status Critical Current Adjusted expiration legal-status Critical Links Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US201361813089P external-priority Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC Priority to US14/254,020 priority Critical patent/US9474757B2/en Assigned to SIGNAL PHARMACEUTICALS LLC reassignment SIGNAL PHARMACEUTICALS LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Original Assignee Signal Pharmaceuticals LLC Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ( en Inventor Kristen Mae Hege Rajesh Chopra Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active, expires Application number US14/254,020 Other versions US20140314753A1 Google Patents Methods for treating cancer using TOR kinase inhibitor combination therapyĭownload PDF Info Publication number US9474757B2 US9474757B2 US14/254,020 US201414254020A US9474757B2 US 9474757 B2 US9474757 B2 US 9474757B2 US 201414254020 A US201414254020 A US 201414254020A US 9474757 B2 US9474757 B2 US 9474757B2 Authority US United States Prior art keywords compound lymphoma alkyl cancer substituted Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US9474757B2 - Methods for treating cancer using TOR kinase inhibitor combination therapy began his journey 90 years ago, and our dedication to making things grow is as strong as ever.US9474757B2 - Methods for treating cancer using TOR kinase inhibitor combination therapy The Company’s Core Values – Passion for People, Spirit of Innovation and Respect for Resources – are as relevant now as they were when J.R. Its major operations in the U.S., Canada, Mexico, Australia, Argentina and China provide a diverse array of products and services to people around the world. Our integrated portfolio includes farming, ranching and cattle production, food processing, food brands, phosphate mining, fertilizer manufacturing, and other enterprises related to agriculture. The Company leads innovations in plant nutrition and food processing, researches new ways to feed animals and sustain ecosystems, and works with farmers and partners to help feed a growing global population. Still privately held and headquartered in Boise, Idaho, Simplot has grown into an international food and agriculture company with more than 13,000 employees worldwide. That served him well when he was sorting potatoes for Idaho farmers in the 1930s, feeding the troops in WWII, and introducing the world to the first marketable frozen french fry. believed that making something grow, meant seeing opportunities where others saw obstacles. Through the years, J.R.’s belief in the promise of the possible helped him diversify his efforts into a global food and agriculture business.įrom the very beginning, J.R. was armed with keen entrepreneurial instincts, constant curiosity, boundless energy and an irrepressible drive. Simplot Company began to take shape in the farm fields of southern Idaho in the late 1920s.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |